Abstract 1867P
Background
Health literacy of patients is a requirement for shared decision making. However, little is known about the experiences of patients with lymphoma with regard to health literacy and information disclosure from their treating physicians. We sought to explore health literacy through a survey deployed across a large and diverse group of patients with lymphoma.
Methods
The 2022 Lymphoma Coalition (LC) Global Patient Survey (GPS) was completed by 7113 patients from 84 countries. We sought to understand how patients initially understood their disease. Responses to the question: “To what extent, if at all, were diagnostic tests and results explained to you?” were stratified across core demographics and tabulated. Tests for significant differences across strata were computed with JMP Pro v17.
Results
Of the 6684 respondents who indicated a level of satisfaction or dissatisfaction with regard to the comprehension of diagnostic and laboratory tests, 58% and 42% were males and females respectively with a median age of 60 and range of 18 - 97 years. Overall, 36% of respondents reported poor comprehension. Increasing age was a significant positive predictor of health literacy with a Range OR = 6.9 [5.4 - 8.9]. Likewise, male biological sex was a significant predictor of improved comprehension OR = 1.5 [1.3 - 1.6]. Regional disparities were identified that indicated North America and Europe had the highest rates of satisfactory comprehension with 72% and 68% respectively. This was contrasted with the Asia-Pacific region at 53% (p<0.0001).
Conclusions
One of the goals of precision medicine is to deliver the right therapeutics to the right patient at the right time. [LW1] Shared decision making has the ability for patients to provide valuable feedback to their treating physicians. However, a lack of health literacy essentially excludes patients from participating in the decision making process. All three demographics examined above indicated highly significant disparities that can have adverse ramifications on healthcare equity. We feel that patients should understand their disease and the available treatment options which will yield increased participation in their care.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
AbbVie, BMS, Pharmacyclics and Roche.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
2018P - Novel nomogram based on the expression of DLL3 and PD-L1 for predicting the prognosis of small cell lung cancer patients
Presenter: Jun Zhao
Session: Poster session 05
2019P - Analysis of lung immune prognostic index (LIPI) score in a small cell lung cancer carcinoma (SCLC) cohort, supporting its prognostic use and investigating its predictive potential
Presenter: Mónica Esteban García
Session: Poster session 05
2020P - Circulating micro RNAs (cmiRNAs) as treatment outcome predictors in extensive small cell lung cancer (eSCLC) patients (pts) receiving atezolizumab plus carboplatin and etoposide (ACE): CATS/ML43257 study
Presenter: Giulia Pasello
Session: Poster session 05
2021P - Cell-free (cf) DNA as predictive biomarker (B) of treatment outcome in extensive small cell lung cancer (eSCLC) patients (pts) receiving atezolizumab, carboplatin and etoposide (ACE): CATS/ML43257 study
Presenter: Giulia Pasello
Session: Poster session 05
2022P - ALBA project: Prognostic impact of laterality in small cell lung cancer
Presenter: Lorenza Landi
Session: Poster session 05
2024P - Supportive measures to control myelosuppression and costs for patients with SCLC with lurbinectedin, CAV or topotecan with or without trilaciclib: A review on the basis of clinical trials
Presenter: Manuel Dómine
Session: Poster session 05
2025P - Stratified control study of neuroendocrine differentiation and potential clinicopathologic markers
Presenter: Li Liu
Session: Poster session 05
2026P - Small cell lung cancer (SCLC) in the KBP-2020-CPHG cohort and comparison with 2000 and 2010
Presenter: Lionel Falchero
Session: Poster session 05
2027P - Immune checkpoint inhibitors in the treatment of small cell lung cancer: A systematic review and meta-analysis
Presenter: Patsy Lee
Session: Poster session 05